| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 184 | 2024 | 841 | 27.610 |
Why?
|
| Kidney Failure, Chronic | 166 | 2024 | 861 | 26.750 |
Why?
|
| Renal Insufficiency, Chronic | 92 | 2023 | 713 | 13.320 |
Why?
|
| Kidney Transplantation | 71 | 2024 | 621 | 11.140 |
Why?
|
| Kidney Diseases | 51 | 2024 | 477 | 8.350 |
Why?
|
| Anemia | 37 | 2023 | 338 | 7.770 |
Why?
|
| Atrial Fibrillation | 32 | 2024 | 621 | 7.000 |
Why?
|
| Hematinics | 31 | 2023 | 57 | 6.890 |
Why?
|
| Nephrology | 39 | 2023 | 144 | 6.590 |
Why?
|
| Peritoneal Dialysis | 21 | 2023 | 118 | 5.980 |
Why?
|
| Medicare | 44 | 2023 | 418 | 4.890 |
Why?
|
| Anticoagulants | 22 | 2024 | 582 | 4.660 |
Why?
|
| Glomerular Filtration Rate | 43 | 2022 | 480 | 4.540 |
Why?
|
| Kidney | 44 | 2023 | 1340 | 4.440 |
Why?
|
| Erythropoietin | 21 | 2023 | 104 | 4.290 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 22 | 2021 | 210 | 4.120 |
Why?
|
| Aged | 197 | 2024 | 18785 | 4.000 |
Why?
|
| Myocardial Infarction | 28 | 2023 | 994 | 3.950 |
Why?
|
| United States | 140 | 2024 | 10487 | 3.810 |
Why?
|
| Hip Fractures | 8 | 2020 | 66 | 3.790 |
Why?
|
| Warfarin | 11 | 2022 | 119 | 3.460 |
Why?
|
| Humans | 439 | 2024 | 122296 | 3.380 |
Why?
|
| Acute Kidney Injury | 21 | 2022 | 606 | 3.360 |
Why?
|
| Male | 262 | 2024 | 59522 | 3.140 |
Why?
|
| Middle Aged | 182 | 2024 | 25640 | 3.130 |
Why?
|
| Female | 271 | 2024 | 64883 | 3.030 |
Why?
|
| Renal Replacement Therapy | 11 | 2021 | 141 | 2.940 |
Why?
|
| Stroke | 22 | 2022 | 957 | 2.890 |
Why?
|
| Cardiovascular Diseases | 36 | 2022 | 1822 | 2.800 |
Why?
|
| Risk Assessment | 41 | 2024 | 3307 | 2.780 |
Why?
|
| Glomerulonephritis | 6 | 2019 | 73 | 2.750 |
Why?
|
| Hemorrhage | 13 | 2024 | 457 | 2.530 |
Why?
|
| Terminology as Topic | 10 | 2020 | 226 | 2.510 |
Why?
|
| Aged, 80 and over | 75 | 2024 | 6291 | 2.490 |
Why?
|
| Angiotensin Receptor Antagonists | 9 | 2021 | 121 | 2.470 |
Why?
|
| Risk Factors | 87 | 2023 | 9902 | 2.390 |
Why?
|
| Renal Insufficiency | 9 | 2024 | 232 | 2.340 |
Why?
|
| Medicaid | 19 | 2019 | 239 | 2.250 |
Why?
|
| Hypertension | 17 | 2024 | 1274 | 2.240 |
Why?
|
| Incidence | 42 | 2022 | 3018 | 2.220 |
Why?
|
| Cohort Studies | 65 | 2022 | 4643 | 2.200 |
Why?
|
| Iron | 14 | 2023 | 263 | 2.030 |
Why?
|
| Cause of Death | 20 | 2019 | 451 | 1.980 |
Why?
|
| Proportional Hazards Models | 34 | 2021 | 1298 | 1.970 |
Why?
|
| Practice Patterns, Physicians' | 15 | 2021 | 710 | 1.970 |
Why?
|
| Diabetic Nephropathies | 9 | 2019 | 110 | 1.950 |
Why?
|
| Hypoglycemic Agents | 10 | 2022 | 412 | 1.900 |
Why?
|
| Cardiovascular Agents | 7 | 2012 | 86 | 1.870 |
Why?
|
| Prognosis | 39 | 2023 | 4488 | 1.830 |
Why?
|
| Retrospective Studies | 86 | 2024 | 15853 | 1.790 |
Why?
|
| Time Factors | 57 | 2024 | 6182 | 1.740 |
Why?
|
| Adult | 100 | 2024 | 28733 | 1.660 |
Why?
|
| Treatment Outcome | 70 | 2024 | 12045 | 1.650 |
Why?
|
| Blood Pressure | 10 | 2023 | 1314 | 1.600 |
Why?
|
| Ferric Compounds | 5 | 2023 | 37 | 1.580 |
Why?
|
| Delivery of Health Care | 5 | 2020 | 604 | 1.550 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 10 | 2010 | 51 | 1.550 |
Why?
|
| Coronary Artery Bypass | 9 | 2016 | 486 | 1.520 |
Why?
|
| Hospitalization | 25 | 2021 | 1727 | 1.500 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2022 | 1204 | 1.500 |
Why?
|
| Antihypertensive Agents | 12 | 2021 | 392 | 1.500 |
Why?
|
| Graft Survival | 17 | 2019 | 522 | 1.500 |
Why?
|
| Diabetes Mellitus | 13 | 2020 | 845 | 1.490 |
Why?
|
| Mortality | 8 | 2018 | 222 | 1.450 |
Why?
|
| Prospective Payment System | 6 | 2021 | 16 | 1.440 |
Why?
|
| Follow-Up Studies | 41 | 2022 | 5013 | 1.410 |
Why?
|
| Fibrinolytic Agents | 3 | 2024 | 199 | 1.400 |
Why?
|
| Referral and Consultation | 9 | 2012 | 525 | 1.400 |
Why?
|
| Glycine | 7 | 2022 | 167 | 1.400 |
Why?
|
| Altitude | 4 | 2012 | 22 | 1.380 |
Why?
|
| Caregivers | 7 | 2022 | 561 | 1.380 |
Why?
|
| Heparin | 6 | 2014 | 229 | 1.380 |
Why?
|
| Arteriovenous Shunt, Surgical | 7 | 2024 | 94 | 1.380 |
Why?
|
| Heart Failure | 15 | 2021 | 2125 | 1.370 |
Why?
|
| Coronary Disease | 7 | 2016 | 634 | 1.320 |
Why?
|
| Homocysteine | 7 | 2005 | 120 | 1.310 |
Why?
|
| Survival Rate | 27 | 2022 | 1997 | 1.310 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2017 | 222 | 1.290 |
Why?
|
| Registries | 18 | 2020 | 1367 | 1.260 |
Why?
|
| Renin-Angiotensin System | 5 | 2021 | 95 | 1.260 |
Why?
|
| Glucaric Acid | 4 | 2023 | 10 | 1.260 |
Why?
|
| Population Surveillance | 4 | 2022 | 381 | 1.250 |
Why?
|
| Hyperkalemia | 6 | 2024 | 65 | 1.220 |
Why?
|
| Comorbidity | 21 | 2020 | 1490 | 1.210 |
Why?
|
| Potassium | 7 | 2024 | 279 | 1.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2020 | 711 | 1.190 |
Why?
|
| Hemoglobins | 17 | 2023 | 300 | 1.160 |
Why?
|
| Economic Competition | 4 | 2023 | 14 | 1.120 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2014 | 220 | 1.110 |
Why?
|
| Living Donors | 3 | 2024 | 111 | 1.110 |
Why?
|
| Darbepoetin alfa | 10 | 2023 | 15 | 1.100 |
Why?
|
| Practice Guidelines as Topic | 12 | 2021 | 1244 | 1.100 |
Why?
|
| Thrombosis | 3 | 2024 | 515 | 1.090 |
Why?
|
| Medication Adherence | 4 | 2012 | 384 | 1.090 |
Why?
|
| Coronary Artery Disease | 8 | 2019 | 741 | 1.080 |
Why?
|
| Health Policy | 5 | 2021 | 208 | 1.030 |
Why?
|
| Graft Rejection | 11 | 2019 | 576 | 1.030 |
Why?
|
| Proton Pump Inhibitors | 3 | 2022 | 253 | 1.010 |
Why?
|
| Factor XI | 2 | 2024 | 3 | 0.980 |
Why?
|
| Drug Prescriptions | 10 | 2024 | 215 | 0.980 |
Why?
|
| Anemia, Iron-Deficiency | 6 | 2023 | 132 | 0.960 |
Why?
|
| Glomerulonephritis, IGA | 3 | 2019 | 16 | 0.940 |
Why?
|
| Hyperphosphatemia | 4 | 2016 | 16 | 0.940 |
Why?
|
| Patient Outcome Assessment | 4 | 2020 | 93 | 0.930 |
Why?
|
| Altruism | 1 | 2024 | 26 | 0.930 |
Why?
|
| Kidney Function Tests | 10 | 2022 | 126 | 0.930 |
Why?
|
| National Health Programs | 2 | 2023 | 20 | 0.920 |
Why?
|
| Multivariate Analysis | 21 | 2016 | 1407 | 0.910 |
Why?
|
| Disease Progression | 14 | 2024 | 1991 | 0.900 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2018 | 234 | 0.900 |
Why?
|
| Death, Sudden, Cardiac | 8 | 2022 | 244 | 0.890 |
Why?
|
| Health Services Accessibility | 9 | 2021 | 581 | 0.890 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2024 | 1679 | 0.870 |
Why?
|
| Nephrectomy | 1 | 2024 | 172 | 0.860 |
Why?
|
| Aftercare | 1 | 2024 | 145 | 0.860 |
Why?
|
| Insurance, Health | 4 | 2018 | 134 | 0.860 |
Why?
|
| Young Adult | 33 | 2020 | 8760 | 0.850 |
Why?
|
| Folic Acid | 6 | 2005 | 291 | 0.850 |
Why?
|
| Electronic Health Records | 6 | 2017 | 691 | 0.830 |
Why?
|
| Health Care Costs | 8 | 2020 | 360 | 0.820 |
Why?
|
| Patients | 2 | 2020 | 120 | 0.820 |
Why?
|
| Picolinic Acids | 5 | 2022 | 10 | 0.810 |
Why?
|
| Prolyl-Hydroxylase Inhibitors | 4 | 2023 | 5 | 0.790 |
Why?
|
| Ficus | 1 | 2021 | 2 | 0.780 |
Why?
|
| Coffee | 2 | 2015 | 23 | 0.770 |
Why?
|
| Hypolipidemic Agents | 6 | 2020 | 176 | 0.770 |
Why?
|
| Postoperative Complications | 9 | 2020 | 2997 | 0.770 |
Why?
|
| Logistic Models | 16 | 2020 | 1772 | 0.770 |
Why?
|
| Survival Analysis | 15 | 2018 | 1468 | 0.760 |
Why?
|
| Ambulatory Care | 7 | 2021 | 376 | 0.760 |
Why?
|
| Immunosuppressive Agents | 11 | 2019 | 645 | 0.760 |
Why?
|
| Vitamin B 12 | 4 | 2005 | 55 | 0.750 |
Why?
|
| Caffeine | 2 | 2015 | 69 | 0.750 |
Why?
|
| Diabetes Complications | 2 | 2015 | 197 | 0.750 |
Why?
|
| Central Venous Catheters | 2 | 2018 | 38 | 0.740 |
Why?
|
| Patient Discharge | 4 | 2014 | 487 | 0.740 |
Why?
|
| Decision Making | 5 | 2020 | 650 | 0.740 |
Why?
|
| Drug Utilization | 7 | 2020 | 157 | 0.730 |
Why?
|
| Depression | 3 | 2019 | 1214 | 0.730 |
Why?
|
| Stents | 3 | 2017 | 864 | 0.730 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 360 | 0.720 |
Why?
|
| Lupus Nephritis | 7 | 2015 | 45 | 0.720 |
Why?
|
| Betacoronavirus | 3 | 2020 | 289 | 0.720 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 378 | 0.720 |
Why?
|
| Cross-Sectional Studies | 17 | 2024 | 3301 | 0.710 |
Why?
|
| Isoquinolines | 2 | 2021 | 40 | 0.710 |
Why?
|
| Research Design | 9 | 2018 | 646 | 0.690 |
Why?
|
| Carbonated Beverages | 2 | 2012 | 9 | 0.680 |
Why?
|
| Drug Utilization Review | 4 | 2007 | 33 | 0.670 |
Why?
|
| Thiazolidinediones | 3 | 2010 | 80 | 0.670 |
Why?
|
| Comparative Effectiveness Research | 4 | 2017 | 66 | 0.670 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 1084 | 0.660 |
Why?
|
| Databases, Factual | 13 | 2020 | 1158 | 0.660 |
Why?
|
| Reimbursement Mechanisms | 5 | 2023 | 38 | 0.660 |
Why?
|
| Tacrolimus | 6 | 2019 | 98 | 0.660 |
Why?
|
| Dialysis | 1 | 2019 | 20 | 0.660 |
Why?
|
| Pandemics | 4 | 2021 | 1102 | 0.650 |
Why?
|
| Secondary Prevention | 5 | 2012 | 210 | 0.650 |
Why?
|
| Global Health | 3 | 2020 | 555 | 0.650 |
Why?
|
| Prevalence | 17 | 2022 | 2371 | 0.640 |
Why?
|
| Algorithms | 8 | 2019 | 1575 | 0.640 |
Why?
|
| Guideline Adherence | 4 | 2018 | 376 | 0.630 |
Why?
|
| Pyridines | 3 | 2018 | 222 | 0.630 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 397 | 0.630 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2018 | 76 | 0.630 |
Why?
|
| Metoprolol | 1 | 2018 | 22 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 1034 | 0.620 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 49 | 0.610 |
Why?
|
| Medicare Part D | 2 | 2016 | 17 | 0.610 |
Why?
|
| Adolescent | 34 | 2022 | 18940 | 0.610 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 605 | 0.610 |
Why?
|
| Creatinine | 8 | 2022 | 379 | 0.600 |
Why?
|
| Age Factors | 15 | 2018 | 2777 | 0.600 |
Why?
|
| Employment | 2 | 2018 | 67 | 0.600 |
Why?
|
| Intracranial Hemorrhages | 4 | 2014 | 72 | 0.600 |
Why?
|
| Intensive Care Units | 1 | 2021 | 475 | 0.600 |
Why?
|
| Ferrosoferric Oxide | 2 | 2015 | 26 | 0.600 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2016 | 2573 | 0.590 |
Why?
|
| Albuminuria | 5 | 2020 | 91 | 0.590 |
Why?
|
| Brain Ischemia | 4 | 2019 | 258 | 0.590 |
Why?
|
| Attitude to Health | 3 | 2019 | 255 | 0.590 |
Why?
|
| Patient Compliance | 4 | 2008 | 464 | 0.590 |
Why?
|
| Ambulatory Care Facilities | 7 | 2021 | 228 | 0.580 |
Why?
|
| Hyperparathyroidism | 2 | 2010 | 23 | 0.580 |
Why?
|
| United States Food and Drug Administration | 4 | 2013 | 147 | 0.560 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 2006 | 70 | 0.560 |
Why?
|
| Congresses as Topic | 8 | 2024 | 164 | 0.560 |
Why?
|
| Erythropoiesis | 4 | 2022 | 40 | 0.550 |
Why?
|
| Quality of Life | 12 | 2023 | 1913 | 0.550 |
Why?
|
| Air Pollution | 2 | 2021 | 66 | 0.540 |
Why?
|
| Program Evaluation | 3 | 2018 | 445 | 0.540 |
Why?
|
| Consensus | 13 | 2023 | 606 | 0.540 |
Why?
|
| Epoetin Alfa | 6 | 2016 | 12 | 0.540 |
Why?
|
| Nephrologists | 4 | 2021 | 13 | 0.540 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2017 | 168 | 0.530 |
Why?
|
| Hyperhomocysteinemia | 4 | 2006 | 38 | 0.530 |
Why?
|
| Chelating Agents | 4 | 2016 | 43 | 0.530 |
Why?
|
| Models, Biological | 1 | 2021 | 1438 | 0.530 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2014 | 1099 | 0.520 |
Why?
|
| Barbiturates | 1 | 2015 | 7 | 0.520 |
Why?
|
| Acetates | 3 | 2011 | 72 | 0.520 |
Why?
|
| Blood Glucose | 2 | 2017 | 1103 | 0.520 |
Why?
|
| Confidence Intervals | 9 | 2016 | 277 | 0.520 |
Why?
|
| Air Pollutants | 2 | 2021 | 100 | 0.520 |
Why?
|
| Delayed Graft Function | 2 | 2013 | 2 | 0.510 |
Why?
|
| Health Status | 5 | 2017 | 370 | 0.510 |
Why?
|
| Reimbursement, Incentive | 2 | 2018 | 45 | 0.510 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 252 | 0.510 |
Why?
|
| Administration, Oral | 6 | 2021 | 668 | 0.510 |
Why?
|
| Women's Health | 6 | 2021 | 129 | 0.510 |
Why?
|
| Vascular Diseases | 2 | 2018 | 161 | 0.500 |
Why?
|
| Ferredoxin-NADP Reductase | 2 | 2005 | 10 | 0.500 |
Why?
|
| Terminal Care | 2 | 2014 | 114 | 0.490 |
Why?
|
| Bone Density Conservation Agents | 2 | 2017 | 52 | 0.490 |
Why?
|
| Austria | 10 | 2020 | 22 | 0.490 |
Why?
|
| Fenoldopam | 1 | 2014 | 11 | 0.490 |
Why?
|
| Patient Care Bundles | 2 | 2021 | 23 | 0.490 |
Why?
|
| Publishing | 3 | 2020 | 104 | 0.490 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2016 | 74 | 0.480 |
Why?
|
| Metformin | 2 | 2021 | 137 | 0.480 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 187 | 0.480 |
Why?
|
| Focus Groups | 6 | 2022 | 200 | 0.480 |
Why?
|
| Clonidine | 1 | 2014 | 35 | 0.480 |
Why?
|
| Dialysis Solutions | 4 | 2024 | 10 | 0.480 |
Why?
|
| Polymers | 1 | 2015 | 106 | 0.480 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 24 | 0.470 |
Why?
|
| Healthcare Disparities | 7 | 2024 | 410 | 0.470 |
Why?
|
| Chronic Disease | 11 | 2011 | 1166 | 0.470 |
Why?
|
| Hemodialysis Units, Hospital | 4 | 2020 | 9 | 0.470 |
Why?
|
| Off-Label Use | 2 | 2012 | 25 | 0.460 |
Why?
|
| Depressive Disorder | 1 | 2017 | 450 | 0.460 |
Why?
|
| Phosphates | 3 | 2016 | 112 | 0.460 |
Why?
|
| Plasma Substitutes | 2 | 2003 | 7 | 0.450 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 70 | 0.450 |
Why?
|
| Hydroxyethyl Starch Derivatives | 2 | 2003 | 8 | 0.450 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 54 | 0.450 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 265 | 0.450 |
Why?
|
| Residence Characteristics | 4 | 2013 | 265 | 0.450 |
Why?
|
| Hypotension | 3 | 2020 | 177 | 0.440 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 34 | 0.440 |
Why?
|
| C-Reactive Protein | 3 | 2007 | 405 | 0.440 |
Why?
|
| Cyclosporine | 4 | 2019 | 146 | 0.440 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2014 | 172 | 0.440 |
Why?
|
| Pregnancy Complications | 2 | 2015 | 503 | 0.430 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 203 | 0.430 |
Why?
|
| Thromboembolism | 3 | 2021 | 84 | 0.430 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2013 | 23 | 0.430 |
Why?
|
| Aspirin | 1 | 2014 | 222 | 0.430 |
Why?
|
| Insurance Claim Reporting | 2 | 2012 | 8 | 0.430 |
Why?
|
| Mycophenolic Acid | 3 | 2017 | 51 | 0.430 |
Why?
|
| Case-Control Studies | 9 | 2022 | 3229 | 0.420 |
Why?
|
| Counseling | 1 | 2014 | 218 | 0.420 |
Why?
|
| Polyamines | 3 | 2012 | 28 | 0.420 |
Why?
|
| Qualitative Research | 5 | 2018 | 513 | 0.420 |
Why?
|
| Drinking Behavior | 1 | 2012 | 8 | 0.420 |
Why?
|
| Particulate Matter | 2 | 2021 | 70 | 0.420 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 635 | 0.410 |
Why?
|
| New Jersey | 8 | 2012 | 24 | 0.410 |
Why?
|
| Critical Illness | 2 | 2020 | 588 | 0.410 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 256 | 0.410 |
Why?
|
| Postoperative Hemorrhage | 2 | 2003 | 87 | 0.410 |
Why?
|
| Chlorides | 1 | 2012 | 104 | 0.410 |
Why?
|
| Prospective Studies | 19 | 2022 | 5963 | 0.400 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2012 | 10 | 0.400 |
Why?
|
| Blood Transfusion | 1 | 2014 | 303 | 0.400 |
Why?
|
| Fluid Therapy | 1 | 2012 | 120 | 0.390 |
Why?
|
| Pennsylvania | 5 | 2012 | 46 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 303 | 0.390 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 857 | 0.390 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 161 | 0.390 |
Why?
|
| Biomedical Research | 6 | 2018 | 510 | 0.390 |
Why?
|
| Naphthalenes | 2 | 2012 | 37 | 0.390 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 1283 | 0.390 |
Why?
|
| Ozone | 1 | 2011 | 18 | 0.390 |
Why?
|
| Intestinal Perforation | 1 | 2012 | 59 | 0.390 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2015 | 643 | 0.380 |
Why?
|
| Communication | 3 | 2020 | 505 | 0.380 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2011 | 54 | 0.380 |
Why?
|
| Vitamin D | 2 | 2010 | 157 | 0.370 |
Why?
|
| Tissue and Organ Procurement | 4 | 2021 | 218 | 0.370 |
Why?
|
| Obesity | 2 | 2020 | 2083 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 1008 | 0.370 |
Why?
|
| Health Facility Closure | 2 | 2021 | 8 | 0.370 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2010 | 12 | 0.370 |
Why?
|
| Calcium Carbonate | 1 | 2010 | 11 | 0.370 |
Why?
|
| Postmenopause | 3 | 2015 | 124 | 0.360 |
Why?
|
| Body Mass Index | 5 | 2020 | 1463 | 0.360 |
Why?
|
| Prescription Drugs | 2 | 2012 | 52 | 0.360 |
Why?
|
| Textiles | 2 | 2020 | 10 | 0.360 |
Why?
|
| Sex Distribution | 6 | 2018 | 284 | 0.350 |
Why?
|
| Odds Ratio | 8 | 2021 | 1234 | 0.350 |
Why?
|
| Feeding Behavior | 1 | 2015 | 676 | 0.350 |
Why?
|
| Double-Blind Method | 6 | 2024 | 1568 | 0.350 |
Why?
|
| Masks | 2 | 2020 | 39 | 0.350 |
Why?
|
| Defibrillators, Implantable | 2 | 2018 | 191 | 0.350 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1022 | 0.340 |
Why?
|
| Catheterization, Central Venous | 2 | 2011 | 131 | 0.340 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 31 | 0.340 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 112 | 0.340 |
Why?
|
| Health Services for the Aged | 1 | 2010 | 38 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 815 | 0.340 |
Why?
|
| Endpoint Determination | 4 | 2018 | 52 | 0.340 |
Why?
|
| Recombinant Proteins | 7 | 2015 | 1370 | 0.330 |
Why?
|
| Sevelamer | 4 | 2016 | 10 | 0.330 |
Why?
|
| Anaphylaxis | 1 | 2010 | 77 | 0.330 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 96 | 0.330 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 60 | 0.310 |
Why?
|
| Blood Coagulation | 2 | 2024 | 118 | 0.310 |
Why?
|
| Administration, Intravenous | 4 | 2017 | 142 | 0.310 |
Why?
|
| Models, Statistical | 9 | 2015 | 447 | 0.310 |
Why?
|
| Phosphorus | 2 | 2011 | 55 | 0.300 |
Why?
|
| Cost-Benefit Analysis | 7 | 2013 | 492 | 0.300 |
Why?
|
| International Classification of Diseases | 2 | 2006 | 89 | 0.300 |
Why?
|
| Drugs, Generic | 2 | 2020 | 13 | 0.300 |
Why?
|
| Venous Thrombosis | 2 | 2013 | 182 | 0.300 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 729 | 0.300 |
Why?
|
| Pulmonary Embolism | 2 | 2013 | 172 | 0.290 |
Why?
|
| Health Care Sector | 2 | 2018 | 19 | 0.290 |
Why?
|
| Myocardial Revascularization | 1 | 2008 | 96 | 0.290 |
Why?
|
| Hyperlipidemias | 3 | 2020 | 174 | 0.290 |
Why?
|
| Patient Participation | 3 | 2020 | 216 | 0.290 |
Why?
|
| Transplant Recipients | 4 | 2018 | 210 | 0.290 |
Why?
|
| Hemodialysis, Home | 4 | 2023 | 13 | 0.290 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 2080 | 0.290 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2015 | 784 | 0.290 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 266 | 0.280 |
Why?
|
| Hospital Mortality | 5 | 2019 | 996 | 0.280 |
Why?
|
| Length of Stay | 4 | 2008 | 1273 | 0.280 |
Why?
|
| Benzodiazepines | 1 | 2007 | 98 | 0.280 |
Why?
|
| Patient Readmission | 4 | 2020 | 364 | 0.280 |
Why?
|
| Hemodialysis Solutions | 3 | 2024 | 5 | 0.280 |
Why?
|
| Anti-Anxiety Agents | 1 | 2007 | 72 | 0.280 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 2817 | 0.280 |
Why?
|
| Propensity Score | 7 | 2021 | 203 | 0.270 |
Why?
|
| Losartan | 1 | 2006 | 33 | 0.270 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 17 | 0.270 |
Why?
|
| Causality | 2 | 2017 | 78 | 0.270 |
Why?
|
| Diagnosis-Related Groups | 2 | 2006 | 28 | 0.270 |
Why?
|
| Hematocrit | 4 | 2011 | 111 | 0.270 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 473 | 0.270 |
Why?
|
| Intraoperative Care | 2 | 2003 | 104 | 0.270 |
Why?
|
| Patient Preference | 5 | 2019 | 100 | 0.260 |
Why?
|
| Calcium | 3 | 2011 | 1095 | 0.260 |
Why?
|
| Drug-Eluting Stents | 2 | 2017 | 53 | 0.260 |
Why?
|
| Patient Care Planning | 3 | 2019 | 122 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 5 | 2011 | 104 | 0.260 |
Why?
|
| Biomarkers | 9 | 2024 | 2933 | 0.260 |
Why?
|
| Citalopram | 2 | 2022 | 30 | 0.250 |
Why?
|
| Health Expenditures | 3 | 2022 | 102 | 0.250 |
Why?
|
| Outpatients | 2 | 2019 | 252 | 0.250 |
Why?
|
| Consensus Development Conferences as Topic | 6 | 2020 | 39 | 0.250 |
Why?
|
| Sertraline | 2 | 2022 | 44 | 0.250 |
Why?
|
| Anemia, Hypochromic | 1 | 2004 | 8 | 0.240 |
Why?
|
| Regression Analysis | 5 | 2015 | 755 | 0.240 |
Why?
|
| Statistics as Topic | 2 | 2015 | 244 | 0.240 |
Why?
|
| Risk | 5 | 2013 | 744 | 0.240 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 156 | 0.240 |
Why?
|
| 5,10-Methylenetetrahydrofolate Reductase (FADH2) | 1 | 2004 | 4 | 0.240 |
Why?
|
| Silicates | 1 | 2024 | 11 | 0.240 |
Why?
|
| Erythrocytes | 2 | 2005 | 206 | 0.240 |
Why?
|
| Health Resources | 2 | 2017 | 115 | 0.240 |
Why?
|
| Data Mining | 2 | 2016 | 52 | 0.240 |
Why?
|
| Torsades de Pointes | 2 | 2024 | 6 | 0.240 |
Why?
|
| Coronary Angiography | 1 | 2007 | 417 | 0.240 |
Why?
|
| Forearm | 1 | 2024 | 44 | 0.240 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 227 | 0.240 |
Why?
|
| Transcobalamins | 1 | 2004 | 4 | 0.240 |
Why?
|
| Vascular Access Devices | 2 | 2014 | 35 | 0.230 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 98 | 0.230 |
Why?
|
| Therapeutics | 1 | 2004 | 7 | 0.230 |
Why?
|
| Chi-Square Distribution | 6 | 2013 | 585 | 0.230 |
Why?
|
| Blood Pressure Determination | 3 | 2020 | 105 | 0.230 |
Why?
|
| Health Surveys | 2 | 2021 | 235 | 0.230 |
Why?
|
| Complement Activation | 1 | 2024 | 50 | 0.230 |
Why?
|
| Morbidity | 3 | 2020 | 239 | 0.230 |
Why?
|
| Vocabulary, Controlled | 2 | 2020 | 13 | 0.230 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 3626 | 0.230 |
Why?
|
| Delphi Technique | 4 | 2020 | 200 | 0.230 |
Why?
|
| Oligonucleotides | 1 | 2024 | 88 | 0.230 |
Why?
|
| Transplantation, Homologous | 6 | 2023 | 659 | 0.220 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2003 | 6 | 0.220 |
Why?
|
| Analysis of Variance | 5 | 2012 | 1004 | 0.220 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 304 | 0.220 |
Why?
|
| Physicians | 2 | 2014 | 582 | 0.220 |
Why?
|
| Comprehension | 2 | 2020 | 73 | 0.220 |
Why?
|
| Antigens, Surface | 1 | 2003 | 122 | 0.210 |
Why?
|
| Time | 2 | 2016 | 92 | 0.210 |
Why?
|
| Germany | 1 | 2022 | 86 | 0.210 |
Why?
|
| Embolism | 1 | 2022 | 48 | 0.200 |
Why?
|
| Hypokalemia | 2 | 2019 | 41 | 0.200 |
Why?
|
| Genotype | 6 | 2019 | 2525 | 0.200 |
Why?
|
| Waiting Lists | 3 | 2021 | 220 | 0.200 |
Why?
|
| Nephrosis, Lipoid | 2 | 2019 | 10 | 0.200 |
Why?
|
| Diuretics | 2 | 2021 | 158 | 0.200 |
Why?
|
| Health Facility Merger | 2 | 2019 | 8 | 0.200 |
Why?
|
| Azithromycin | 1 | 2022 | 45 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 428 | 0.200 |
Why?
|
| Ferritins | 5 | 2023 | 95 | 0.200 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 174 | 0.200 |
Why?
|
| Preventive Health Services | 1 | 2002 | 53 | 0.200 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 278 | 0.200 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2022 | 25 | 0.200 |
Why?
|
| Patient Safety | 4 | 2015 | 389 | 0.200 |
Why?
|
| Calcium Compounds | 3 | 2011 | 7 | 0.190 |
Why?
|
| Symporters | 1 | 2022 | 65 | 0.190 |
Why?
|
| Annual Reports as Topic | 1 | 2021 | 2 | 0.190 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2002 | 118 | 0.190 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2021 | 8 | 0.190 |
Why?
|
| Respiratory Tract Diseases | 1 | 2022 | 77 | 0.190 |
Why?
|
| Genetic Testing | 2 | 2019 | 978 | 0.190 |
Why?
|
| Age Distribution | 3 | 2015 | 400 | 0.190 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 144 | 0.190 |
Why?
|
| Mathematical Concepts | 1 | 2021 | 7 | 0.190 |
Why?
|
| Cost of Illness | 3 | 2019 | 239 | 0.190 |
Why?
|
| Uremia | 1 | 2001 | 35 | 0.190 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 805 | 0.180 |
Why?
|
| Australia | 5 | 2020 | 140 | 0.180 |
Why?
|
| Poverty | 2 | 2014 | 412 | 0.180 |
Why?
|
| Transferrin | 4 | 2013 | 51 | 0.180 |
Why?
|
| Neoplasms | 5 | 2020 | 2753 | 0.180 |
Why?
|
| Inpatients | 2 | 2019 | 487 | 0.180 |
Why?
|
| Frustration | 1 | 2020 | 9 | 0.180 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 457 | 0.180 |
Why?
|
| Drug Costs | 4 | 2015 | 61 | 0.180 |
Why?
|
| Hospitals, Veterans | 2 | 2021 | 353 | 0.180 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 65 | 0.180 |
Why?
|
| Saphenous Vein | 2 | 2013 | 53 | 0.180 |
Why?
|
| Vitamin K | 1 | 2020 | 35 | 0.180 |
Why?
|
| Minority Groups | 2 | 2013 | 249 | 0.180 |
Why?
|
| Polypharmacy | 1 | 2020 | 40 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 501 | 0.170 |
Why?
|
| Monitoring, Physiologic | 2 | 2012 | 357 | 0.170 |
Why?
|
| Mitral Valve Stenosis | 1 | 2019 | 34 | 0.170 |
Why?
|
| Education | 1 | 2020 | 105 | 0.170 |
Why?
|
| Optic Nerve Diseases | 1 | 2001 | 87 | 0.170 |
Why?
|
| Safety-net Providers | 1 | 2019 | 41 | 0.170 |
Why?
|
| Students, Medical | 1 | 2004 | 357 | 0.170 |
Why?
|
| United Kingdom | 2 | 2020 | 189 | 0.160 |
Why?
|
| Patient Care Team | 2 | 2017 | 539 | 0.160 |
Why?
|
| Patient Selection | 3 | 2011 | 685 | 0.160 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2019 | 12 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2020 | 308 | 0.160 |
Why?
|
| Fear | 1 | 2020 | 201 | 0.160 |
Why?
|
| Health Personnel | 2 | 2020 | 500 | 0.160 |
Why?
|
| Dabigatran | 1 | 2018 | 25 | 0.160 |
Why?
|
| Biometry | 2 | 2017 | 129 | 0.160 |
Why?
|
| Self-Management | 1 | 2020 | 96 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2021 | 217 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2021 | 195 | 0.160 |
Why?
|
| Interviews as Topic | 2 | 2017 | 367 | 0.160 |
Why?
|
| Brain Death | 1 | 2019 | 55 | 0.160 |
Why?
|
| Mesenteric Ischemia | 1 | 2018 | 29 | 0.160 |
Why?
|
| Sex Factors | 6 | 2015 | 1238 | 0.150 |
Why?
|
| Endocarditis | 1 | 2019 | 103 | 0.150 |
Why?
|
| Death | 1 | 2019 | 71 | 0.150 |
Why?
|
| Public Health | 3 | 2016 | 252 | 0.150 |
Why?
|
| Rivaroxaban | 1 | 2018 | 55 | 0.150 |
Why?
|
| Calcinosis | 1 | 2019 | 167 | 0.150 |
Why?
|
| Thiazoles | 1 | 2018 | 96 | 0.150 |
Why?
|
| Heart Arrest | 1 | 2022 | 341 | 0.150 |
Why?
|
| Office Visits | 2 | 2017 | 75 | 0.150 |
Why?
|
| Unemployment | 1 | 2018 | 19 | 0.150 |
Why?
|
| Medically Uninsured | 2 | 2019 | 73 | 0.150 |
Why?
|
| Injections, Intravenous | 3 | 2014 | 254 | 0.150 |
Why?
|
| Policy Making | 1 | 2018 | 58 | 0.150 |
Why?
|
| Commerce | 1 | 2018 | 50 | 0.150 |
Why?
|
| Cost Savings | 2 | 2015 | 69 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1015 | 0.150 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 154 | 0.150 |
Why?
|
| Skilled Nursing Facilities | 1 | 2017 | 5 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 111 | 0.150 |
Why?
|
| Costs and Cost Analysis | 4 | 2015 | 161 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 187 | 0.150 |
Why?
|
| Self Medication | 1 | 2017 | 23 | 0.150 |
Why?
|
| Anuria | 1 | 2017 | 13 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 271 | 0.150 |
Why?
|
| Tissue Donors | 4 | 2019 | 498 | 0.150 |
Why?
|
| Parathyroid Hormone | 2 | 2011 | 72 | 0.140 |
Why?
|
| Family Health | 2 | 2019 | 258 | 0.140 |
Why?
|
| Acute Disease | 3 | 2021 | 1090 | 0.140 |
Why?
|
| Program Development | 1 | 2018 | 189 | 0.140 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2022 | 437 | 0.140 |
Why?
|
| Azathioprine | 1 | 2017 | 54 | 0.140 |
Why?
|
| Veterans Health | 1 | 2018 | 172 | 0.140 |
Why?
|
| Pravastatin | 2 | 2007 | 23 | 0.140 |
Why?
|
| HIV | 1 | 2018 | 179 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2012 | 336 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 1 | 2016 | 55 | 0.140 |
Why?
|
| Metals | 1 | 2017 | 60 | 0.140 |
Why?
|
| Insurance Coverage | 1 | 2017 | 121 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 208 | 0.140 |
Why?
|
| Health Care Rationing | 2 | 2021 | 58 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 347 | 0.130 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 102 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2019 | 426 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 426 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2001 | 430 | 0.130 |
Why?
|
| Computer Simulation | 3 | 2017 | 607 | 0.130 |
Why?
|
| Societies, Medical | 3 | 2020 | 673 | 0.130 |
Why?
|
| Financing, Government | 1 | 2016 | 30 | 0.130 |
Why?
|
| Glycemic Index | 1 | 2015 | 18 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2018 | 300 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 151 | 0.130 |
Why?
|
| Drinking | 1 | 2015 | 34 | 0.130 |
Why?
|
| Physician-Patient Relations | 2 | 2017 | 423 | 0.130 |
Why?
|
| Poisson Distribution | 2 | 2015 | 48 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2017 | 179 | 0.130 |
Why?
|
| BK Virus | 1 | 2016 | 58 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 322 | 0.130 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 1147 | 0.130 |
Why?
|
| Inappropriate Prescribing | 1 | 2015 | 41 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2003 | 1520 | 0.130 |
Why?
|
| Alleles | 3 | 2005 | 1579 | 0.120 |
Why?
|
| Menopause | 1 | 2015 | 73 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 74 | 0.120 |
Why?
|
| Parents | 2 | 2022 | 1016 | 0.120 |
Why?
|
| Polyomavirus Infections | 1 | 2016 | 88 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 2016 | 135 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2017 | 163 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 124 | 0.120 |
Why?
|
| International Cooperation | 2 | 2017 | 160 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2015 | 145 | 0.120 |
Why?
|
| Half-Life | 1 | 2015 | 159 | 0.120 |
Why?
|
| Coronary Restenosis | 1 | 2014 | 20 | 0.120 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 35 | 0.120 |
Why?
|
| Contraindications | 1 | 2014 | 77 | 0.120 |
Why?
|
| Insurance Claim Review | 2 | 2014 | 24 | 0.120 |
Why?
|
| Canada | 4 | 2019 | 294 | 0.120 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 422 | 0.120 |
Why?
|
| Hemoglobin A | 1 | 2014 | 22 | 0.120 |
Why?
|
| Digoxin | 1 | 2014 | 43 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2014 | 26 | 0.120 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 711 | 0.120 |
Why?
|
| Cardiology | 1 | 2019 | 468 | 0.120 |
Why?
|
| Linear Models | 4 | 2015 | 657 | 0.110 |
Why?
|
| Drug Approval | 2 | 2012 | 39 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2016 | 229 | 0.110 |
Why?
|
| Hemoglobinometry | 1 | 2013 | 4 | 0.110 |
Why?
|
| Capitation Fee | 1 | 2013 | 3 | 0.110 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2013 | 13 | 0.110 |
Why?
|
| Haplotypes | 1 | 2015 | 510 | 0.110 |
Why?
|
| Ownership | 3 | 2019 | 30 | 0.110 |
Why?
|
| Urological Agents | 1 | 2013 | 3 | 0.110 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 29 | 0.110 |
Why?
|
| United Nations | 1 | 2013 | 13 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2013 | 20 | 0.110 |
Why?
|
| Transplantation | 1 | 2013 | 29 | 0.110 |
Why?
|
| Adiposity | 1 | 2014 | 181 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2015 | 482 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 2 | 2015 | 176 | 0.110 |
Why?
|
| Catheterization | 1 | 2014 | 238 | 0.110 |
Why?
|
| Observation | 1 | 2012 | 41 | 0.100 |
Why?
|
| Health Care Reform | 3 | 2020 | 50 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2004 | 703 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2019 | 646 | 0.100 |
Why?
|
| Motivation | 1 | 2014 | 312 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 828 | 0.100 |
Why?
|
| Internal Medicine | 2 | 2011 | 147 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 539 | 0.100 |
Why?
|
| Orphan Drug Production | 1 | 2012 | 5 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 804 | 0.100 |
Why?
|
| Forecasting | 1 | 2013 | 355 | 0.100 |
Why?
|
| Long-Term Care | 1 | 2012 | 71 | 0.100 |
Why?
|
| Bone Density | 1 | 2014 | 307 | 0.100 |
Why?
|
| Postoperative Period | 4 | 2022 | 330 | 0.100 |
Why?
|
| California | 1 | 2012 | 127 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 542 | 0.100 |
Why?
|
| Kidney Glomerulus | 2 | 2024 | 83 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2013 | 527 | 0.100 |
Why?
|
| Government Agencies | 1 | 2011 | 11 | 0.090 |
Why?
|
| Recurrence | 3 | 2016 | 1413 | 0.090 |
Why?
|
| Netherlands | 2 | 2011 | 36 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 394 | 0.090 |
Why?
|
| Aging | 2 | 2010 | 1165 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 168 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 2796 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 1 | 2010 | 15 | 0.090 |
Why?
|
| Spironolactone | 1 | 2010 | 18 | 0.090 |
Why?
|
| Mutation | 1 | 2004 | 5734 | 0.090 |
Why?
|
| Stem Cells | 2 | 2013 | 710 | 0.090 |
Why?
|
| Child | 12 | 2022 | 24064 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2017 | 972 | 0.090 |
Why?
|
| Palliative Care | 1 | 2014 | 424 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2011 | 163 | 0.090 |
Why?
|
| Renal Elimination | 2 | 2019 | 9 | 0.080 |
Why?
|
| Electrocardiography | 2 | 2023 | 963 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2013 | 460 | 0.080 |
Why?
|
| Analgesics | 1 | 2010 | 131 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 125 | 0.080 |
Why?
|
| Geography | 1 | 2009 | 112 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2011 | 351 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 2010 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 3 | 2014 | 202 | 0.080 |
Why?
|
| Internationality | 2 | 2020 | 128 | 0.080 |
Why?
|
| Anxiety | 2 | 2022 | 950 | 0.080 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 162 | 0.080 |
Why?
|
| Lung | 1 | 2016 | 1476 | 0.080 |
Why?
|
| Receptors, Angiotensin | 1 | 2007 | 21 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2011 | 391 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 279 | 0.070 |
Why?
|
| Stakeholder Participation | 2 | 2018 | 25 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 350 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 1192 | 0.070 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 8 | 0.070 |
Why?
|
| Prolactin | 1 | 2007 | 104 | 0.070 |
Why?
|
| Lovastatin | 1 | 2007 | 25 | 0.070 |
Why?
|
| Heparin Antagonists | 1 | 2007 | 5 | 0.070 |
Why?
|
| Patient Admission | 1 | 2008 | 184 | 0.070 |
Why?
|
| Simvastatin | 1 | 2007 | 75 | 0.070 |
Why?
|
| Bacteremia | 1 | 2011 | 405 | 0.070 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 77 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 267 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2007 | 134 | 0.070 |
Why?
|
| Isosorbide Dinitrate | 1 | 2005 | 4 | 0.070 |
Why?
|
| Hydralazine | 1 | 2005 | 8 | 0.070 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2006 | 95 | 0.070 |
Why?
|
| Alberta | 2 | 2016 | 43 | 0.070 |
Why?
|
| Indians, North American | 2 | 2018 | 58 | 0.070 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2005 | 10 | 0.070 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 134 | 0.070 |
Why?
|
| Body Height | 1 | 2007 | 205 | 0.060 |
Why?
|
| Equipment Failure | 1 | 2006 | 122 | 0.060 |
Why?
|
| Hemarthrosis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Diet Surveys | 1 | 2005 | 95 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1191 | 0.060 |
Why?
|
| Pyrroles | 1 | 2007 | 177 | 0.060 |
Why?
|
| Pregnancy | 2 | 2015 | 7092 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 238 | 0.060 |
Why?
|
| Biopsy | 2 | 2019 | 1246 | 0.060 |
Why?
|
| Blood Coagulation Factors | 1 | 2005 | 35 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2004 | 21 | 0.060 |
Why?
|
| Hemophilia A | 1 | 2005 | 20 | 0.060 |
Why?
|
| Child, Preschool | 7 | 2017 | 13777 | 0.060 |
Why?
|
| Prednisolone | 2 | 2004 | 73 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 594 | 0.060 |
Why?
|
| Polyethylenes | 1 | 2004 | 8 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 230 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2004 | 18 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2005 | 95 | 0.060 |
Why?
|
| Complement Inactivating Agents | 1 | 2024 | 11 | 0.060 |
Why?
|
| Inflammation | 2 | 2018 | 1392 | 0.060 |
Why?
|
| Arm | 1 | 2024 | 75 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 2385 | 0.060 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2005 | 106 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2024 | 58 | 0.060 |
Why?
|
| Europe | 2 | 2021 | 369 | 0.060 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 65 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2005 | 594 | 0.060 |
Why?
|
| Prolyl Hydroxylases | 1 | 2023 | 3 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2006 | 230 | 0.060 |
Why?
|
| Calcium Channel Agonists | 1 | 2003 | 12 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2023 | 23 | 0.050 |
Why?
|
| Cholesterol | 1 | 2006 | 521 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2024 | 86 | 0.050 |
Why?
|
| Fasting | 1 | 2004 | 298 | 0.050 |
Why?
|
| Calcitriol | 1 | 2003 | 82 | 0.050 |
Why?
|
| Fluvoxamine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 514 | 0.050 |
Why?
|
| Direct Service Costs | 1 | 2002 | 8 | 0.050 |
Why?
|
| Value of Life | 1 | 2002 | 9 | 0.050 |
Why?
|
| Transferrins | 1 | 2022 | 2 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2005 | 292 | 0.050 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2002 | 20 | 0.050 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2022 | 4 | 0.050 |
Why?
|
| Paroxetine | 1 | 2022 | 29 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2022 | 43 | 0.050 |
Why?
|
| Social Values | 1 | 2002 | 47 | 0.050 |
Why?
|
| Allografts | 1 | 2023 | 186 | 0.050 |
Why?
|
| Hepcidins | 1 | 2022 | 20 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 581 | 0.050 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2002 | 32 | 0.050 |
Why?
|
| Ischemia | 2 | 2006 | 342 | 0.050 |
Why?
|
| Bradycardia | 1 | 2022 | 60 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 67 | 0.050 |
Why?
|
| Homozygote | 1 | 2004 | 521 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2022 | 46 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2002 | 51 | 0.050 |
Why?
|
| Bias | 1 | 2002 | 113 | 0.050 |
Why?
|
| Ultrafiltration | 1 | 2021 | 12 | 0.050 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 19 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2004 | 163 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 39 | 0.050 |
Why?
|
| Heterozygote | 1 | 2004 | 675 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3050 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2006 | 541 | 0.050 |
Why?
|
| Retreatment | 1 | 2001 | 88 | 0.050 |
Why?
|
| Mammography | 1 | 2002 | 113 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2001 | 106 | 0.050 |
Why?
|
| Ireland | 1 | 2021 | 23 | 0.050 |
Why?
|
| Amoxicillin | 1 | 2022 | 118 | 0.050 |
Why?
|
| Reoperation | 1 | 2004 | 807 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 247 | 0.050 |
Why?
|
| Smoking | 1 | 2007 | 1028 | 0.050 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2000 | 26 | 0.050 |
Why?
|
| Pyridoxine | 1 | 2000 | 14 | 0.050 |
Why?
|
| International Agencies | 1 | 2020 | 28 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 290 | 0.050 |
Why?
|
| Social Class | 1 | 2001 | 180 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1592 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1022 | 0.040 |
Why?
|
| Health Facilities, Proprietary | 1 | 2019 | 3 | 0.040 |
Why?
|
| Data Collection | 1 | 2022 | 383 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2001 | 117 | 0.040 |
Why?
|
| Diabetic Retinopathy | 1 | 2002 | 157 | 0.040 |
Why?
|
| Health Literacy | 1 | 2020 | 79 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 286 | 0.040 |
Why?
|
| Base Sequence | 1 | 2004 | 3109 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2019 | 45 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 217 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 19 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 84 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1579 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 17 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 213 | 0.040 |
Why?
|
| Paraproteinemias | 1 | 2019 | 16 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 385 | 0.040 |
Why?
|
| Aorta | 1 | 2022 | 534 | 0.040 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3865 | 0.040 |
Why?
|
| Growth | 1 | 2019 | 107 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 276 | 0.040 |
Why?
|
| Urea | 1 | 2019 | 210 | 0.040 |
Why?
|
| Cadaver | 2 | 2011 | 132 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2005 | 822 | 0.040 |
Why?
|
| Health Facilities | 1 | 2018 | 59 | 0.040 |
Why?
|
| Podocytes | 1 | 2019 | 79 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 386 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 122 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 176 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2017 | 2 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2019 | 245 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 282 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 875 | 0.040 |
Why?
|
| Seasons | 1 | 2019 | 300 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2019 | 446 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 89 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 397 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 698 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 512 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 2018 | 246 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2015 | 46 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 738 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 127 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 252 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2015 | 522 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 131 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 194 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2015 | 18 | 0.030 |
Why?
|
| Culture | 1 | 2015 | 66 | 0.030 |
Why?
|
| Cost Control | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 217 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 304 | 0.030 |
Why?
|
| Health Priorities | 1 | 2015 | 36 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2014 | 84 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 872 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 496 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 511 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 665 | 0.030 |
Why?
|
| Progestins | 1 | 2014 | 47 | 0.030 |
Why?
|
| Inventions | 1 | 2013 | 17 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 115 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 798 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 28 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 251 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 218 | 0.030 |
Why?
|
| Reticulocytes | 1 | 2012 | 42 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2012 | 83 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2015 | 379 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1871 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 171 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3528 | 0.030 |
Why?
|
| Infant | 3 | 2016 | 12302 | 0.020 |
Why?
|
| Lidocaine | 1 | 2012 | 48 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 164 | 0.020 |
Why?
|
| Neuralgia | 1 | 2012 | 44 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2018 | 853 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 65 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 596 | 0.020 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 19 | 0.020 |
Why?
|
| Estrogens | 1 | 2014 | 506 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 54 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 182 | 0.020 |
Why?
|
| Organization and Administration | 1 | 2010 | 4 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2016 | 8096 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2009 | 27 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 576 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2009 | 111 | 0.020 |
Why?
|
| Software | 1 | 2014 | 670 | 0.020 |
Why?
|
| Pediatrics | 1 | 2018 | 1140 | 0.020 |
Why?
|
| Decision Trees | 1 | 2007 | 48 | 0.020 |
Why?
|
| Educational Status | 1 | 2008 | 267 | 0.020 |
Why?
|
| Logical Observation Identifiers Names and Codes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Hospital Records | 1 | 2006 | 8 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2006 | 10 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 105 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2006 | 56 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 114 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2006 | 122 | 0.020 |
Why?
|
| Phosphatidylglycerols | 1 | 2005 | 5 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 2005 | 13 | 0.020 |
Why?
|
| Factor VII | 1 | 2005 | 15 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2005 | 41 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 189 | 0.020 |
Why?
|
| Factor VIIa | 1 | 2005 | 23 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 319 | 0.020 |
Why?
|
| Fluconazole | 1 | 2005 | 47 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 194 | 0.020 |
Why?
|
| Models, Economic | 1 | 2005 | 51 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2005 | 90 | 0.020 |
Why?
|
| Factor VIII | 1 | 2005 | 45 | 0.020 |
Why?
|
| Home Care Services | 1 | 2005 | 66 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 288 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 266 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 20 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 90 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 419 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2006 | 291 | 0.010 |
Why?
|
| Triglycerides | 1 | 2006 | 560 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2005 | 418 | 0.010 |
Why?
|
| Critical Care | 1 | 2007 | 647 | 0.010 |
Why?
|
| Animals | 1 | 2000 | 33721 | 0.010 |
Why?
|